ORIC Pharmaceuticals (ORIC) Competitors $9.59 +0.47 (+5.15%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ORIC vs. PHAT, IPHA, KPTI, ARQT, BTAI, ZLAB, CPRX, IOVA, SRRK, and TWSTShould you be buying ORIC Pharmaceuticals stock or one of its competitors? The main competitors of ORIC Pharmaceuticals include Phathom Pharmaceuticals (PHAT), Innate Pharma (IPHA), Karyopharm Therapeutics (KPTI), Arcutis Biotherapeutics (ARQT), BioXcel Therapeutics (BTAI), Zai Lab (ZLAB), Catalyst Pharmaceuticals (CPRX), Iovance Biotherapeutics (IOVA), Scholar Rock (SRRK), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry. ORIC Pharmaceuticals vs. Phathom Pharmaceuticals Innate Pharma Karyopharm Therapeutics Arcutis Biotherapeutics BioXcel Therapeutics Zai Lab Catalyst Pharmaceuticals Iovance Biotherapeutics Scholar Rock Twist Bioscience Phathom Pharmaceuticals (NASDAQ:PHAT) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment, dividends and community ranking. Is PHAT or ORIC more profitable? ORIC Pharmaceuticals has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -1,292.14%. Phathom Pharmaceuticals' return on equity of 0.00% beat ORIC Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals-1,292.14% N/A -79.57% ORIC Pharmaceuticals N/A -42.47%-38.86% Do institutionals & insiders have more ownership in PHAT or ORIC? 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.1% of ORIC Pharmaceuticals shares are owned by institutional investors. 24.1% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 5.6% of ORIC Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, PHAT or ORIC? Phathom Pharmaceuticals has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Does the media favor PHAT or ORIC? In the previous week, ORIC Pharmaceuticals had 6 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 8 mentions for ORIC Pharmaceuticals and 2 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.91 beat ORIC Pharmaceuticals' score of -0.35 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ORIC Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts recommend PHAT or ORIC? Phathom Pharmaceuticals presently has a consensus target price of $22.50, indicating a potential upside of 140.90%. ORIC Pharmaceuticals has a consensus target price of $18.29, indicating a potential upside of 90.67%. Given Phathom Pharmaceuticals' higher possible upside, research analysts clearly believe Phathom Pharmaceuticals is more favorable than ORIC Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, PHAT or ORIC? ORIC Pharmaceuticals has lower revenue, but higher earnings than Phathom Pharmaceuticals. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhathom Pharmaceuticals$26.27M24.31-$201.59M-$5.69-1.64ORIC PharmaceuticalsN/AN/A-$100.70M-$1.80-5.33 Does the MarketBeat Community prefer PHAT or ORIC? Phathom Pharmaceuticals received 24 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. However, 72.09% of users gave ORIC Pharmaceuticals an outperform vote while only 71.67% of users gave Phathom Pharmaceuticals an outperform vote. CompanyUnderperformOutperformPhathom PharmaceuticalsOutperform Votes8671.67% Underperform Votes3428.33% ORIC PharmaceuticalsOutperform Votes6272.09% Underperform Votes2427.91% SummaryORIC Pharmaceuticals beats Phathom Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Ad Brownstone ResearchShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Click here for full details. Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORIC vs. The Competition Export to ExcelMetricORIC PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$676.77M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-5.3311.10105.1417.83Price / SalesN/A362.031,233.15158.41Price / CashN/A52.5940.4136.29Price / Book2.4710.377.096.50Net Income-$100.70M$153.60M$119.65M$226.22M7 Day Performance12.82%4.60%2.25%4.03%1 Month Performance8.73%-6.29%-2.33%4.92%1 Year Performance31.37%33.41%33.98%29.30% ORIC Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORICORIC Pharmaceuticals4.2201 of 5 stars$9.59+5.2%$18.29+90.7%+31.4%$676.77MN/A-5.3380Gap UpPHATPhathom Pharmaceuticals2.628 of 5 stars$9.43+8.0%$22.50+138.7%+33.6%$644.48M$680,000.00-1.64110IPHAInnate Pharma2.2218 of 5 stars$1.57-7.1%$11.50+632.5%-31.1%$127.12M$66.71M0.00220Gap DownKPTIKaryopharm Therapeutics3.9437 of 5 stars$0.77-1.3%$5.00+550.2%+18.9%$96.37M$146.03M-0.68380Analyst DowngradeNews CoverageARQTArcutis Biotherapeutics1.7743 of 5 stars$10.31+1.3%$15.50+50.3%+439.4%$1.21B$59.61M-5.84150BTAIBioXcel Therapeutics4.6209 of 5 stars$0.57-3.4%$5.00+776.3%-86.7%$24.39M$1.38M-0.2690News CoverageGap DownZLABZai Lab2.9466 of 5 stars$25.70-2.0%$52.50+104.3%-3.9%$2.56B$266.72M-9.312,175High Trading VolumeCPRXCatalyst Pharmaceuticals4.7017 of 5 stars$21.12-0.1%$31.14+47.5%+55.0%$2.52B$398.20M17.86167IOVAIovance Biotherapeutics4.1005 of 5 stars$8.24+1.2%$22.33+171.0%+58.5%$2.51B$1.19M-5.53500SRRKScholar Rock4.2047 of 5 stars$26.74-4.0%$34.00+27.2%+164.1%$2.50B$33.19M-11.38140TWSTTwist Bioscience3.7933 of 5 stars$41.89+1.9%$51.78+23.6%+77.4%$2.49B$312.97M-11.57990Analyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Phathom Pharmaceuticals Competitors Innate Pharma Competitors Karyopharm Therapeutics Competitors Arcutis Biotherapeutics Competitors BioXcel Therapeutics Competitors Zai Lab Competitors Catalyst Pharmaceuticals Competitors Iovance Biotherapeutics Competitors Scholar Rock Competitors Twist Bioscience Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORIC) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ORIC Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
